187 related articles for article (PubMed ID: 7481823)
21. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
Wu S; Gorski J
Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
[TBL] [Abstract][Full Text] [Related]
22. Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as allele-independent supermotifs.
Geluk A; Van Meijgaarden KE; Drijfhout JW; Ottenhoff TH
Mol Immunol; 1995 Sep; 32(13):975-81. PubMed ID: 7477003
[TBL] [Abstract][Full Text] [Related]
23. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
Powis SJ
FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
[TBL] [Abstract][Full Text] [Related]
24. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC.
Liang MN; Beeson C; Mason K; McConnell HM
Int Immunol; 1995 Sep; 7(9):1397-404. PubMed ID: 7495747
[TBL] [Abstract][Full Text] [Related]
26. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
[TBL] [Abstract][Full Text] [Related]
27. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP).
Zhong G; Castellino F; Romagnoli P; Germain RN
J Exp Med; 1996 Nov; 184(5):2061-6. PubMed ID: 8920896
[TBL] [Abstract][Full Text] [Related]
28. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
Demotz S; Danieli C
Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
[TBL] [Abstract][Full Text] [Related]
29. Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines.
Riberdy JM; Avva RR; Geuze HJ; Cresswell P
J Cell Biol; 1994 Jun; 125(6):1225-37. PubMed ID: 8207055
[TBL] [Abstract][Full Text] [Related]
30. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1.
Park SJ; Sadegh-Nasseri S; Wiley DC
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):11289-93. PubMed ID: 7479981
[TBL] [Abstract][Full Text] [Related]
31. Direct observation of disordered regions in the major histocompatibility complex class II-associated invariant chain.
Jasanoff A; Park SJ; Wiley DC
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9900-4. PubMed ID: 7568241
[TBL] [Abstract][Full Text] [Related]
32. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
33. Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.
van Luijn MM; van de Loosdrecht AA; Lampen MH; van Veelen PA; Zevenbergen A; Kester MG; de Ru AH; Ossenkoppele GJ; van Hall T; van Ham SM
PLoS One; 2012; 7(4):e34649. PubMed ID: 22563374
[TBL] [Abstract][Full Text] [Related]
34. Determination of the HLA-DM interaction site on HLA-DR molecules.
Doebele RC; Busch R; Scott HM; Pashine A; Mellins ED
Immunity; 2000 Oct; 13(4):517-27. PubMed ID: 11070170
[TBL] [Abstract][Full Text] [Related]
35. pH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH.
Hausmann DH; Yu B; Hausmann S; Wucherpfennig KW
J Exp Med; 1999 Jun; 189(11):1723-34. PubMed ID: 10359576
[TBL] [Abstract][Full Text] [Related]
36. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
[TBL] [Abstract][Full Text] [Related]
37. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii.
Jasanoff A; Wagner G; Wiley DC
EMBO J; 1998 Dec; 17(23):6812-8. PubMed ID: 9843486
[TBL] [Abstract][Full Text] [Related]
38. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules.
Malcherek G; Gnau V; Jung G; Rammensee HG; Melms A
J Exp Med; 1995 Feb; 181(2):527-36. PubMed ID: 7836909
[TBL] [Abstract][Full Text] [Related]
39. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
[TBL] [Abstract][Full Text] [Related]
40. Structural insights into human MHC-II association with invariant chain.
Wang N; Waghray D; Caveney NA; Jude KM; Garcia KC
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2403031121. PubMed ID: 38687785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
